Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...

Amgen reported fourth-quarter 2024 adjusted ... up 10% from the year-ago period. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, recorded ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen specializes in oncology ... bolstered by a 41% increase in BLINCYTO revenue and a strong launch of IMDELLTRA for small cell lung cancer. Biosimilar sales reached $2.2 billion, marking ...

Amgen successfully launched two next-generation ... Lumakras/Lumykras, Tezspire, Imdelltra, Tavneos and Kanjinti, Mvasi and Amgevita biosimilars. AMGN is a #3 (Hold) on the Zacks Rank, with ...

Amgen’s product sales are expected to have ... respectively. The U.S. launch of Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, is ...

Amgen highlighted its robust performance in ... driven by BLINCYTO and IMDELLTRA. Biosimilar sales increased 16%, with the launch of PAVBLU generating $31 million in just nine weeks.